Business
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
-- IMCIVREE® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval -- --
About this update from Rhythm Pharmaceuticals, Inc.
[{"type":"text","content":"-- IMCIVREE® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval -- -- IMCIVREE now available in eight ex-U.S. markets; first commercial sales for BBS expected in Germany in 2Q 2023 -- -- Pivotal Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity initiated -- -- Acquired Xinvento B.V., a rare disease company in preclinical development for congenital hyperinsulinism -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022. “Rhythm had a very strong 2022. Following U.S. Food and Drug Administration (FDA) approval in June, we successfully launched IMCIVREE® (setmelanotide) for Bardet-Biedl syndrome (BBS) in the United States, and we’ve continued to extend our reach globally, with IMCIVREE now available in eight international markets,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. “With compelling Phase 2 data in hypothalamic obesity and FDA alignment on our pivotal trial design, we recently began screening patients for our Phase 3 study. We look forward to working toward the achievement of several additional clinical milestones in 2023 as we aim to expand the reach of setmelanotide as the first and only precision medicine to address the needs of patients and families living with hyperphagia and severe obesity caused by rare MC4R pathway diseases.” Dr. Meeker continued, “With the acquisition of Xinvento, we are excited to expand our pipeline into congenital hyperinsulinism (CHI), a rare disease that is well aligned with our corporate strategy and broadens our focus into an adjacent endocrine indication with a high unmet need.” Fourth Quarter and Recent Business Highlights Bardet-Biedl Syndrome Today, Rhythm announced that it received more than 200 new prescriptions for IMCIVREE for BBS from more than 125 physicians in the United States with reimbursement approva...